Key result
Intravenous abciximab during carotid stenting in high-risk patients yielded a 3% ischemic stroke rate versus 12% with heparin, but was offset by a 5% rate of intracranial hemorrhage.
Why the study?
Does intravenously administered abciximab reduce perioperative ischemic complications in high-risk patients undergoing carotid angioplasty and stent placement?
Population
70 patients undergoing carotid angioplasty and stent placement, comprising 37 high-risk patients and 33…
Comparison
Abciximab administered intravenously as a single… vs Standard intraprocedural heparinization during…
Design
Cohort
Follow-up
During hospitalization
Authors
Loading...
May reduce ischemic strokes but increase hemorrhage in carotid stenting; leaves open net benefit pending randomized trials.
Cohort (n=70)
Does intravenously administered abciximab reduce perioperative ischemic complications in high-risk patients undergoing carotid angioplasty and stent placement?
Absolute Event Rate: 3% vs 12%
Adjunctive intravenous abciximab during carotid angioplasty and stenting in high-risk patients may reduce ischemic strokes but carries an unacceptably high risk of intracranial hemorrhage.
Qureshi et al. (2002) conducted a cohort in Carotid artery stenosis (n=70). Intravenously administered abciximab vs. Standard intraprocedural heparinization was evaluated on Ischemic stroke. Intravenous abciximab during carotid stenting in high-risk patients yielded a 3% ischemic stroke rate versus 12% with heparin, but was offset by a 5% rate of intracranial hemorrhage.